Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TREH | O43280 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664627 | 1.00 | TREH (0.33) | TREHLGALS3LMNAGBA1 | |
| SCHEMBL27530918 | 1.00 | TREH (0.33) | TREHLGALS3LMNAGBA1 | |
| SCHEMBL900085 | 1.00 | TREH (0.33) | TREHLGALS3LMNAGBA1 | |
| SCHEMBL13191462 | 0.77 | TREH (0.33) | TREHLGALS3LMNAGBA1 | |
| SCHEMBL6669019 | 0.77 | LMNA (0.39) | TREHLGALS3LMNAGBA1 | |
| SCHEMBL28310370 | 0.73 | — | — | |
| SCHEMBL9006292 | 0.73 | — | — | |
| SCHEMBL4423849 | 0.73 | — | — | |
| SCHEMBL8539709 | 0.70 | OGA (0.38) | TREH | |
| SCHEMBL9571760 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113260635-B | Oligosaccharide compositions and methods of use thereof | DSM营养产品有限责任公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116490192-A | Oligosaccharide compositions and methods of use thereof | DSM营养产品有限责任公司 | 2023-07-25 | — | — | CN | claimed |
| CN-116113404-A | Oligosaccharide compositions and methods of use thereof | DSM营养产品有限责任公司 | 2023-05-12 | — | — | CN | claimed |
| EP-2300026-A2 | COMPOSITIONS OBTAINED FROM CHLORELLA EXTRACT HAVING IMMUNOMODULATING PROPERTIES | Ocean Nutrition Canada Limited (CA) | 2011-03-30 | — | — | EP | claimed |
| WO-2009136296-A2 | COMPOSITIONS OBTAINED FROM CHLORELLA EXTRACT HAVING IMMUNOMODULATING PROPERTIES | OCEAN NUTRITION CANADA LIMITED (CA) | 2009-11-12 | — | — | WO | claimed |
| CN-113260635-B | Oligosaccharide compositions and methods of use thereof | DSM营养产品有限责任公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116940368-A | American ginseng root part, preparation method and application thereof | 杰奎琳·J·单 | 2023-10-24 | — | — | CN | disclosed |
| CN-116490192-A | Oligosaccharide compositions and methods of use thereof | DSM营养产品有限责任公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116113404-A | Oligosaccharide compositions and methods of use thereof | DSM营养产品有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022123016-A1 | COSMETIC SUBSTRATE OF NATURAL ORIGIN | L'OREAL (FR) | 2022-06-16 | — | — | WO | disclosed |
| US-20210315810-A1 | COMPOSITION CONTAINING A MUCOLYTIC AGENT FOR THE TREATMENT OF MUCUS HYPERSECRETION AND A DEVICE FOR THE DOSING THEREOF | SOFAR S.P.A. (IT) | 2021-10-14 | — | — | US | disclosed |
| EP-2877481-A1 | ORGANIC COMPOUNDS | Callaghan Innovation Research Limited (NZ) | 2015-06-03 | — | — | EP | disclosed |
| US-20140235850-A1 | SYNTHESIS OF HMO CORE STRUCTURES | GLYCOM A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| WO-2014017928-A1 | ORGANIC COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-01-30 | — | — | WO | disclosed |
| EP-2300026-A2 | COMPOSITIONS OBTAINED FROM CHLORELLA EXTRACT HAVING IMMUNOMODULATING PROPERTIES | Ocean Nutrition Canada Limited (CA) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009136296-A2 | COMPOSITIONS OBTAINED FROM CHLORELLA EXTRACT HAVING IMMUNOMODULATING PROPERTIES | OCEAN NUTRITION CANADA LIMITED (CA) | 2009-11-12 | — | — | WO | disclosed |
| EP-0705059-A4 | CHOLESTEROL SEQUESTRANT GLYCOSIDES THAT INHIBIT INTESTINAL CHOLESTEROL ABSORPTION | OREGON MEDICAL RES FOUND (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0705059-A1 | CHOLESTEROL SEQUESTRANT GLYCOSIDES THAT INHIBIT INTESTINAL CHOLESTEROL ABSORPTION | Oregon Regional Primate Research Center (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1996007743-A1 | XYLOGLUCAN-SPECIFIC BETA-GALACTOSIDASE | UNILEVER PLC (GB) | 1996-03-14 | — | — | WO | disclosed |
| WO-1995023215-A1 | A PROCESS FOR PRODUCING VIRUSES, VIRAL PROTEINS AND RECOMBINANT PROTEINS | THE UNIVERSITY OF QUEENSLAND (AU) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235850-A1 | SYNTHESIS OF HMO CORE STRUCTURES | GNE, OGT, GALE | TREH 358/4885LGALS3 165/4885LMNA 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.